Sentences with phrase «nonsmall cell lung»

This drug has already staked its claim in the world of next - gen «checkpoint inhibitor» cancer treatments by besting rival Bristol - Myers Squibb's competing treatment Opdivo in advanced non-small cell lung cancer (NSCLC).

The company has been trying to win FDA approval for Opdivo to be used as a first option treatment for non-small cell lung cancer (NSCLC).

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

With lung cancer, for example, it wants to be able to resolve whether a test shows non-small-cell lung carcinoma or small cell lung carcinoma.

They'll also jointly market Pfizer's drug Xalkori, which is approved in more than 75 countries for treating non-small cell lung cancer in patients with a certain genetic mutation.

Merck already has an FDA approved immunotherapy drug with KEYTRUDA, a treatment for non-small cell lung cancer.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

Non — small cell lung cancer may involve genetic aberrations that can be used to direct therapy.

«Cause of chemoresistance in small cell lung cancer discovered.»

Approximately one year after successful treatment with cytotoxic chemotherapy and radiotherapy, patients with advanced Small Cell Lung Cancer (SCLC), which primarily affects heavy smokers, generally relapse with recurrence of tumours that are resistant to further chemotherapy.

A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo - radiotherapy of small cell lung cancer (SCLC).

The study, published April 4 in the journal The Lancet Oncology, focused on non-small cell lung cancer, which is the most common form of lung cancer.

In a head - to - head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous - non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.

The abstract title was: Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit.?

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.

For the new trial, hospitals enrolled patients with advanced, squamous non-small cell lung cancer whose disease had progressed despite initial chemotherapy.

The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.

Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies.

Dr. Weiss» study of pembrolizumab was presented during a session on small cell lung cancer when the theme of the conference was Science Drives Lung Cancer Advances.

One, in which Dr. Weiss was the senior author, highlighted the extended survival of metastatic small cell lung cancer (SCLC) patients who received statins.

«Link between inherited genetic variations, outcomes of non-small cell lung cancer patients discovered.»

«We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer.»

The drug erlotinib is prescribed to between 10 — 30 per cent of patients with non-small cell lung cancer, which accounts for 85 per cent of all lung cancer cases.

Until now, EGFR inhibitors have only been effective at treating the 10 to 15 percent of non-small cell lung cancers that have a variant of EGFR, but the two - drug combo could potentially work for all non-small cell lung cancers, explained Dr. John Minna, Director of the Hamon Center for Therapeutic Oncology Research and Professor of Internal Medicine and Pharmacology.

Stagljar and his colleagues also applied the new technology, which they dubbed MaMTH (for Mammalian - Membrane Two - Hybrid assay), to identify a protein that plays a role in the most common form of lung cancer called non-small cell lung cancer.

The FDA has approved several ALK inhibitors for treating non-small cell lung cancer.

The estimation of EGFR mutation status is essential for the identification of non-small cell lung carcinoma (NSCLC) patients who may benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs), and hence for improving therapeutic efficacy.

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

After a median follow - up of 11 months, 11 of the 13 patients who responded remain on the study, including one patient who had non-small cell lung cancer (NSCLC) with a ROS1 gene fusion who has had a complete response that has been maintained for more than two years.

One successful compound, named Exel 647, that targets nonsmall - cell lung cancer in previously untreated patients is now in a phase 2 clinical trial.

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

Some patients with non-small cell lung cancer (NSCLC) have changes in the anaplastic lymphoma kinase (ALK) gene, which can drive the development of their cancer.

Nana - Sinkam and his colleagues examined lung - tumor samples from 81 patients with stage - 1 nonsmall - cell lung cancer and tumor - cell lines.

The study, recently published in the journal Oncotarget, set out to determine whether neratinib could be utilized, alone or in combination with other agents, to kill non-small cell lung cancer (NSCLC) cells that had become resistant to the drug afatinib.

The importance of these neighbour proteins was also seen in other networks constructed for breast cancer, hepatocellular carcinoma and non-small cell lung cancer, other «solid» cancers where new drugs are needed to tackle high mortality rates.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Around 1,600 people are diagnosed with non-small cell lung cancer in Greater Manchester every year and a proportion of these patients will have the ALK - positive type.

One of those genes, K - Ras, which was discovered nearly 30 years ago, is mutated in 30 percent of human tumors, including 90 percent of pancreatic cancers, 40 percent of colon cancers, and 20 percent of non-small cell lung cancers.

«High concordance between EGFR mutations from circulating - free tumor DNA and tumor tissue in non-small cell lung cancer.»

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

One postdoc presents data on her efforts to develop an organoid model for small - cell lung cancer; another reports progress on culturing hormone - secreting organoids from human gut tissue.